Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen

Award Number: R01CA264048
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/13/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen - Project Summary Abstract Colorectal cancer (CRC) is among the most common malignancy worldwide and has a high mortality rate. In spite of advances in our understanding of the genetics and immunology of CRC, it remains largely resistant to therapy. Colonization of the large intestine by oral microbes is common among healthy individuals. Many of these commensals have pathophysiological effects in CRC patients. However, their mechanism of action is unclear. Our recent study identified Parvimonas micra as the most enriched oral bacteria in CRC patient stool and colon mucosa relative to healthy individuals. Networks of P. micra and other oral commensal in the stool of CRC patients excluded protective commensals. Changes in DNA methylation of a set of cardinal genes in the colon mucosa and blood of the patients predicted CRC risk. Transfer of CRC stool to germ free mice that were treated with AOM resulted in DNA methylation of the host and formation of aberrant crypt foci, over and above that observed with transfer of microbiota from healthy individuals. We provided preliminary data that P. micra can directly methylate human colon tumor cells when co-cultured together under hypoxic conditions. On the basis of these findings we hypothesize that oral commensals exemplified by Parvimonas alter DNA methylation of host DNA to adapt to tumors and promote CRC. We will address this in two Specific Aims. 1. We will test the hypothesis that in mouse models of spontaneous CRC, P. micra alters DNA methylation and expression of host genes that affect CRC tumor growth and tumor associate immunity. Mice prone to spontaneous CRC will get healthy human microbiota with or without P. micra, or L. acidophilus for comparison. Reduced representation bisulfite sequencing (RRBS), ATACseq, RNAseq, immune assays, and histopathology will determine how changes in DNA methylation impacts, (1) the growth and invasion of CRC tumors, (2) tumor associated inflammation and immune response, (3) microbial community composition of the tumor mucosa and stool. 2. We will test the hypothesis that P. micra and bacterial community networks regulate tumor growth and immune response in CRC by altering DNA methylation of host cells. To test this we will, (1) Identify clusters of fecal and tissue-adherent bacteria in CRC patients and relate these to the DNA hypermethylation of patient colon and blood across different CMS subclasses, (2) determine how altered DNA methylation of tumor and blood relate to mutation load and immune response, (3) distinguish pathogenic versus protective patterns of DNA methylation in colon epithelial organoids, that result from exposure to P. micra, versus L. acidophilus.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $606,007 )
2025	2025	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	5	9/11/2025	NON-COMPETING CONTINUATION	$606,007
														Subtotal = $606,007

Issue Date FY: 2024 ( Subtotal = $575,706 )
2024	2024	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	001	4	7/30/2024	NON-COMPETING CONTINUATION	$575,706
2024	2023	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	3	12/11/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $575,706

Issue Date FY: 2023 ( Subtotal = $593,887 )
2023	2023	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	3	8/31/2023	NON-COMPETING CONTINUATION	$593,887
														Subtotal = $593,887

Issue Date FY: 2022 ( Subtotal = $645,347 )
2022	2022	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	2	8/31/2022	NON-COMPETING CONTINUATION	$645,347
														Subtotal = $645,347

Issue Date FY: 2021 ( Subtotal = $647,791 )
2021	2021	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Cancer Biology Research	000	1	9/13/2021	NEW	$647,791
														Subtotal = $647,791

Grand Total All Awards = $3,068,738

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen

Award Number: R01CA264048

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/13/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer